Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

BACKGROUND: Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain. METHODS: We assessed the cost-effectiveness of ranibizumab compared with no ranibizumab o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurley, Susan F, Matthews, Jane P, Guymer, Robyn H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443361/
https://www.ncbi.nlm.nih.gov/pubmed/18573218
http://dx.doi.org/10.1186/1478-7547-6-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443361/
https://www.ncbi.nlm.nih.gov/pubmed/18573218
http://dx.doi.org/10.1186/1478-7547-6-12

Ejemplares similares